Medical Device / Healthcare Information Technology - AI-Enhanced Cardiac Diagnostics
Strategic Profile
The company focuses on making ECG a more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. With a micro-cap valuation and early-stage commercial traction, HeartSciences is positioned as a pre-revenue growth play betting on AI-enhanced cardiac diagnostics adoption.
Cyborg Score Rationale
The company currently has negative EPS of -$6.88 with analyst forecasts predicting continued losses of -$3.80 for 2026. Despite forecast revenue growth of 488.3%, the company remains pre-profitability with minimal scale and faces significant execution risk.
Top Insights
Company rebranded from Heart Test Laboratories to HeartSciences Inc. in October 2024, signaling shift toward broader AI-ECG platform positioning
FDA 510(k) submission announced for MyoVista wavECG in December 2025, representing critical regulatory milestone
Only 15 employees indicates early-stage operations with significant scaling needed for commercial success
Q2 2026 EPS of -$0.85 beat estimates by 24.11%, suggesting improved operational efficiency trajectory
Named Competitors
AI-Enhanced Cardiac Monitoring — Established ECG and cardiac monitoring solutions with integrated AI capabilities
Philips CardiacPoint — Integrated ECG and cardiac disease detection platform
Medtronic Cardiac AI Solutions — Large-scale cardiac monitoring and AI diagnostic tools
Recent Developments
(February 2026) Business updates and investor communications enhancements
(December 2025) FDA 510(k) submission for MyoVista wavECG device
(December 2025) Commercial release of MyoVista Insights version 1.1